Buy Stocks Easy | About Us
July 5, 2020
Buy Stocks Easy | Online Stocks

IMRN


Buy Immuron Limited Stock (symbol: IMRN) Easy Online

Company Name: Immuron Limited

Symbol: IMRN

Sector: Health Care

Industry: Major Pharmaceuticals

IPO: 2017

IMRN Current Share Price

Today's IMRN ( Immuron Limited ) opening price: $3.4600

Yesterday's IMRN ( Immuron Limited ) closing price: $3.4300

Immuron Limited Stock ( symbol: IMRN ) Price Chart since IPO (2017):

12 Months Immuron Limited Stock ( symbol: IMRN ) Price Chart

Popular Questions about Immuron Limited Public Stock ( IMRN )

A: Immuron Limited stock symbol (also called stock or share ticker) is IMRN

A: Immuron Limited IPO (Initial Public Offering) took place on 2017

A: Immuron Limited's stock (IMRN symbol) price at ther IPO (initial Public Offering) was $3.4600

Q: Is IMRN stock worth buying at the moment?

A: The IMRN stock performance since 2019 are rather disappointing. If you had bought 1 share of Immuron Limited stock (symbol: IMRN) at the beginning of 2019, at the opening share price of $6.7159, you would be left with exactly $3.4600 - which means a waste of your money and time. - SHOW ONLY IF equal or loose.

Buy Immuron Limited Stock Easy Online

Immuron Limited Stock Ticker Price Chart since IPO:





Immuron Limited Stock Price Yesterday



 


Immuron Limited Stock Price – Last Week




 


Immuron Limited Stock Price – Last Month




 


Immuron Limited Stock Value Chart – 12 Months




            

                

                    

                    
                

                
                
Rate this post

                
            

            
            

             

            

        

    



            



    

        

            

                
 Latest Stock News: 

            

        

        



                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/21/1950673/0/en/Immuron-Plans-Phase-3-trial-for-IMM-124E-to-Prevent-Travelers-Diarrhea.html
                            

                                
Immuron Plans Phase 3 trial for IMM-124E to Prevent Travelers’ Diarrhea

                                
                                
Key Points


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/04/1940505/0/en/Immuron-Receives-AUD-0-53M-R-D-Tax-Concession-Refund.html
                            

                                
Immuron Receives AUD $0.53M R&D Tax Concession Refund

                                
                                
MELBOURNE, Australia, Nov.  04, 2019  (GLOBE NEWSWIRE) -- Immuron L...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/14/1929109/0/en/Immuron-North-American-Q1-Sales-Up-111-YoY.html
                            

                                
Immuron North American Q1 Sales Up 111% YoY

                                
                                
Key Highlights:


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/02/1924135/0/en/New-U-S-Department-of-Defense-Research-Collaboration-with-Immuron-to-Develop-and-Clinically-evaluate-a-New-Therapeutic-against-Campylobacter.html
                            

                                
New U.S. Department of Defense Research Collaboration with Immuron to Develop and Clinically evaluate a New Therapeutic against Campylobacter

                                
                                
Key Highlights:


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/04/1910588/0/en/U-S-Defense-Reports-Immuron-s-Travelan-demonstrates-broad-reactivity-to-Vibrio-cholera-strains-from-Southeast-Asia-indicating-broad-potential-for-prevention-of-travelers-diarrhea.html
                            

                                
U.S. Defense Reports Immuron’s Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad potential for prevention of travelers’ diarrhea

                                
                                
Key Highlights:


                            

                        
                    

                


                            

                    


                        
                            https://www.benzinga.com/general/biotech/19/06/13910287/immuron-rips-higher-on-positive-preclinical-results-for-travelan
                            

                                
Immuron Rips Higher On Positive Preclinical Results For Travelan

                                
                                
Shares of Australian nano-cap biotech Immuron (NASDAQ: IMRN) rose s...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/21/1950673/0/en/Immuron-Plans-Phase-3-trial-for-IMM-124E-to-Prevent-Travelers-Diarrhea.html
                            

                                
Immuron Plans Phase 3 trial for IMM-124E to Prevent Travelers’ Diarrhea

                                
                                
Key Points


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/04/1940505/0/en/Immuron-Receives-AUD-0-53M-R-D-Tax-Concession-Refund.html
                            

                                
Immuron Receives AUD $0.53M R&D Tax Concession Refund

                                
                                
MELBOURNE, Australia, Nov.  04, 2019  (GLOBE NEWSWIRE) -- Immuron L...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/14/1929109/0/en/Immuron-North-American-Q1-Sales-Up-111-YoY.html
                            

                                
Immuron North American Q1 Sales Up 111% YoY

                                
                                
Key Highlights:


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/02/1924135/0/en/New-U-S-Department-of-Defense-Research-Collaboration-with-Immuron-to-Develop-and-Clinically-evaluate-a-New-Therapeutic-against-Campylobacter.html
                            

                                
New U.S. Department of Defense Research Collaboration with Immuron to Develop and Clinically evaluate a New Therapeutic against Campylobacter

                                
                                
Key Highlights:


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/04/1910588/0/en/U-S-Defense-Reports-Immuron-s-Travelan-demonstrates-broad-reactivity-to-Vibrio-cholera-strains-from-Southeast-Asia-indicating-broad-potential-for-prevention-of-travelers-diarrhea.html
                            

                                
U.S. Defense Reports Immuron’s Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad potential for prevention of travelers’ diarrhea

                                
                                
Key Highlights:


                            

                        
                    

                


                            

                    


                        
                            https://www.benzinga.com/general/biotech/19/06/13910287/immuron-rips-higher-on-positive-preclinical-results-for-travelan
                            

                                
Immuron Rips Higher On Positive Preclinical Results For Travelan

                                
                                
Shares of Australian nano-cap biotech Immuron (NASDAQ: IMRN) rose s...


                            

                        
                    

                


            
        

    




    
    





	
	  

	  All right reserved Buy Stocks Easy , 2019.